Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to ...

EQS-AFR: Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...

Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief ...

The collaboration has already yielded strong results, including the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021. In March 2023, the companies reaffirmed their ...

Triggers a $20 million research payment to Evotec, enabling further development of a preclinical program in neurodegeneration ...

HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced another major accomplishment in its long ...

Ongoing strategic partnership advances joint pipeline in neurodegeneration researchEvotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Ev ...

HAMBURG, GERMANY / ACCESS Newswire / February 26, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its Chief Financial Officer ...

Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 HAMBURG, GERMANY / ACCESS Newswire ...

Hamburg-based biotech company Evotec SE faced market pressure on Wednesday following an unexpected leadership change in its finance department. After initially gaining 0.7 percent to reach €8.35 in ...

Evotec SE, the Hamburg-based pharmaceutical research company, is undergoing significant leadership transitions as it navigates through challenging market conditions. The company announced that current ...